Lv5
1506 积分 2024-11-20 加入
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial
1天前
待确认
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
2天前
已完结
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
5天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
5天前
已完结
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
6天前
已完结
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIB trial
8天前
已完结
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
9天前
已完结
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
12天前
已完结
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
19天前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
19天前
已完结
皖公网安备34019202002308
